Healthy
Conditions
Brief summary
The objective of the study is to assess the impact of genetic variation (especially polymorphisms of the gene coding endothelial nitric oxide synthase (eNOS) and the bradykinin B2 receptor gene) on venous and arterial responsiveness to vasodilators in healthy individuals without cardiovascular risk factors.
Detailed description
Study I: Using the dorsal hand vein compliance technique dose-response curves to bradykinin and sodium nitroprusside will be obtained in healthy volunteers during preconstriction with phenylephrine and after pretreatment with a single dose of 500 mg i.v. acetylsalicylic acid. Study II: Using venous occlusion plethysmography dose-response curves to acetylcholine, sodium nitroprusside and L-NG-monomethyl-arginine (L-NMMA) will be obtained in healthy volunteers pretreated with a single dose of 500mg i.v. acetylsalicylic acid.
Interventions
DRUGsodium nitroprusside, bradykinin, acetylcholine
Sponsors
Heidelberg University
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
ECT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* age: 18 - 70 * gender: male * good state of health
Exclusion criteria
* known condition causing endothelial dysfunction (e.g. diabetes, hyperlipidaemia, arterial hypertension, smoking, homocysteinemia) * regular medication and/or treatment with drugs within the last 4-6 weeks (exclusion has to be decided in each case) * acute or chronic illness * methylxanthines and alcohol during 12 hours before the study * nicotine during 1 year before the study * drug and/or alcohol abuse * pregnancy or lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Study I: Venous responsiveness assessed by dorsal hand vein compliance technique | — |
| Study II: Forearm blood flow assessed by venous occlusion plethysmography | — |
Countries
Germany
Contacts
Primary ContactWalter E Haefeli, MD
Outcome results
None listed